Collateral sensitivity to cold stress and differential BCL-2 family expression in new daunomycin-resistant lymphoblastoid cell lines

Experimental Cell Research

Volumn 331, Issue 1, 2015, Pages 11-20

  Cerezo, David ^a   Cánovas, Manuel ^a   García Peñarrubia, Pilar ^a   Martín Orozco, Elena ^a  

^a UNIVERSITY OF MURCIA   (Spain)

Author keywords

Bcl 2; Caspases; Collateral sensitivity; Human lymphoblastic IM 9 cells; MDR; P glycoprotein

Indexed keywords

CASPASE 3; CASPASE 9; DAUNORUBICIN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN BCL 2; ANTINEOPLASTIC ANTIBIOTIC;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL SURVIVAL; CHEMOSENSITIVITY; COLD STRESS; COLLATERAL SENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHOBLASTOID CELL LINE; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; B LYMPHOCYTE; CELL PROLIFERATION; COLD; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; MULTIPLE MYELOMA; PATHOLOGY; PHYSIOLOGICAL STRESS; TUMOR CELL CULTURE; WESTERN BLOTTING;

MURINAE;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; B-LYMPHOCYTES; BLOTTING, WESTERN; CELL PROLIFERATION; COLD TEMPERATURE; DAUNORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MULTIPLE MYELOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; STRESS, PHYSIOLOGICAL; TUMOR CELLS, CULTURED;

EID: 84921322466     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2014.11.017     Document Type: Article

References (38)

1. Shabbits JA, Hu YP, Mayer LD. Tumor chemosensitization strategies based on apoptosis manipulations. Mol. Cancer Ther. 2003, 2:805-813.
2. Hall MD, Misty DH, Gottesman MM. Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol. Sci. 2009, 30(10):546-556.
3. Szakacs G, Paterson JK, Ludwig JK, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006, 5:219-234.
4. Cerezo D, Lencina M, Ruiz-Alcaraz AJ, Ferragut JA, Saceda M, Sanchez M, et al. Acquisition of MDR phenotype by leukemic cells is associated with increased caspase-3 activity and a collateral sensitivity to cold stress. J. Cell. Biochem. 2012, 113(4):1416-1425.
5. Sarkady B, Homolya L, Szakacs G, Varadi A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol. Rev. 2009, 86:1179-1236.
6. Mahadevan D, List AF. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood 2004, 104:1940-1951.
7. Hong L, Piao Y, Han Y, Wang J, Zhang X, Du Y, et al. ZNRD1) mediates multidrug resistance of leukemia cells through regulation of P-glycoprotein and Bcl-2. Mol. Cancer Ther. 2005, 4(12):1936-1942.
8. Zhang X, Yashiro M, Qiu H, Nishii T, Matsuzaki T, Hirakawa K. establishment and characterization of multidrug-resistant gastric cancer cell lines. Anticancer Res. 2010, 30:915-922.
9. Baumgart A, Seidl S, Vlachou P, Michel L, Mitova N, Schatz N, et al. ADAM17 regulates epidermal growth factor receptor expression through the activation of Notch1 in non-small cell lung cancer. Cancer Res. 2010, 70:5368-5378.
10. Mumenthaler SM, Ng PYB, Hodge A, Bearss D, Berk G, Kanekal S, et al. Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol. Cancer Ther. 2009, 8:2882-2893.
11. Kavitha K, Priyadarsini RV, Anitha P, Thiyagarajan P, Nimbolide Nagini S. A neem limonoid abrogates canonical NF-κB and Wnt signaling to induce caspase-dependent apoptosis in human hepatocarcinoma (HepG2) cells. Eur. J. Pharmacol. 2012, 681:6-14.
12. Alexander-Miller MA, Derby MA, Sarin A, Henkart PA, Berzofsky JA. Supraoptimal peptide-major histocompatibility complex causes a decrease in bc1-2 levels and allows tumor necrosis factor alpha receptor II-mediated apoptosis of cytotoxic T lymphocytes. J. Exp. Med. 1998, 188(8):1391-1399.
13. Groesdonk HV, Wagner F, Hoffarth B, Georgieff M, Senftleben U. Enhancement of Nf-kb activation in lymphocytes prevents T cell apoptosis and improves survival in murine sepsis. J. Immunol. 2007, 179(12):8083-8089.
14. Doi K, Li R, Sung S-S, Wu H, Liu Y, Manieri W, et al. Discovery of marinopyrrole A (Maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. J. Biol. Chem. 2012, 287(13):10224-10235.
15. Stout BA, Melendez K, Seagrave JC, et al. STAT1 activation causes translocation of Bax to the endoplasmic reticulum during the resolution of airway mucous cell hyperplasia by IFN-gamma. J. Immunol. 2007, 178:8107-8116.
16. α signaling. FASEB J. 2011, 25:990-1001.
17. Castro-Galache MD, Ferragut JA, Barbera VM, Martin-Orozco E, Gonzalez-Ros JM, Garcia-Morales P, et al. Susceptibility of multidrug resistance tumor cells to apoptosis induction by histone deacetylase inhibitors. Int. J. Cancer 2003, 104:579-586.
18. Pluchino KM, Hall MD, Goldsborough AS, Callaghan R, Gottesman MM. Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist. Updates 2012, 15(1-2):98-105.
19. Johnstone RW, Cretney E, Smyth MJ. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 1999, 93:1075-1085.
20. Ruefli AA, Smyth MJ, Johnstone RW. HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance. Blood 2000, 95:2378-2385.
21. Ruefli AA, Bernhard D, Tainton KM, Kofler R, Smyth M, Johnstone RW. Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells. Int. J. Cancer 2002, 99:292-298.
22. Ruefli AA, Tainton KM, Darcy PK, Smyth MJ, Johnstone RW. P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. Cell Death Differ. 2002, 9:1266-1272.
23. Mizutani T, Masuda M, Nakai E, Furumiya K, Togawa H, Nakamura Y, et al. Genuine functions of P-glycoprotein (ABCB1). Curr. Drug Metab. 2008, 9(2):167-174.
24. Callaghan R, Crowley E, Potter S, Kerr ID. P-glycoprotein: so many ways to turn it on. J. Clin. Pharmacol. 2008, 48:365-378.
25. Wartenberg M, Gronczynska S, Bekhite MM, Saric T, Niedermeier W, Hescheler J, et al. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular prostate tumor spheroids by hyperthermia and reactive oxygen species. Int. J. Cancer 2005, 113:229-240.
26. Seo SB, Hur JG, Kim MJ, Lee JW, Kim HB, Bae JH, et al. TRAIL sensitizes MDR cells to MDR-related drugs by down-regulation of P-glycoprotein through inhibition of DNA-PKcs/Akt/GSK-3b pathway and activation of caspases. Mol. Cancer 2010, 9:199-214.
27. Campone M, Vavasseur F, Le Cabellec MT, Meflah K, Vallette FM, Oliver L Induction of chemoresistance in HL-60 cells concomitantly causes a resistance to apoptosis and the synthesis of P-glycoprotein. Leukemia 2001, 15:1377-1387.
28. Souza PS, Vasconcelos FC, De Souza Reis FR, Nestal de Moraes G, Maia RC. P-glycoprotein and survivin simultaneously regulate vincristine-induced apoptosis in chronic myeloid leukemia cells. Int. J. Oncol. 2011, 39(4):925-933.
29. Bugginsa AGS, Pepper CJ. The role of Bcl-2 family proteins in chronic lymphocytic leukaemia. Leuk. Res. 2010, 34:837-842.
30. Simstein R, Burow M, Parker A, Weldon C, Beckman B. Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. Exp. Biol. Med. 2003, 228:995-1003.
31. Kanamaru Y, Sekine S, Ichijo H, Takeda K. The phosphorylation-dependent regulation of mitochondrial proteins in stress responses. J. Signal Transduct. 2012, 2012:1-12.
32. Gogada R, Prabhu V, Amadori M, Scott R, Hashmi S, Chandra D. Resveratrol induces p53-independent, X-linked inhibitor of apoptosis protein (XIAP)-mediated Bax protein oligomerization on mitochondria to initiate cytochrome c release and caspase activation. J. Biol. Chem. 2011, 286(33):28749-28760.
33. Aliabadi HM, Mahdipoor P, Uludağ H. Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells. Cancer Gene Ther. 2013, 20:169-177.
34. Campbell KJ, Bath ML, Turner ML, Vanderberg CJ, Bouillet P, Metcalf D, et al. Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance. Blood 2010, 116(17):3197-3207.
35. Cuconati A, Mukherjee C, Perez D, White E. DNA damage response and MCL-1 destruction initiate apoptosisin adenovirus-infected cells. Genes Dev. 2003, 17:2922-2932.
36. Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F, Wang X. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev. 2003, 17:1475-1496.
37. Gélinas C, White E. BH3-only proteins in control: specificity regulates MCL-1 and BAK-mediated apoptosis. Genes Dev. 2005, 19:1263-1268.
38. Gillissen B, Wendt J, Richter A, Richter A, Müer A, Overkamp T, et al. Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma. J. Cell Biol. 2010, 188(6):851-862.